Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC

(MedPage Today) -- NEW ORLEANS -- Neoadjuvant combinations involving durvalumab (Imfinzi) plus novel agents led to major pathological responses (MPRs) in nearly a third of patients with early-stage non-small cell lung cancer (NSCLC), a phase...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news